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Abstract
Objectives The aim of the study was to assess cardiac
involvement in patients with Wegener’s granulomatosis
(WG), who failed to achieve remission following >6 months
induction therapy for life or organ threatening disease.
Methods Eleven WG patients (eight males, mean age 47±
13 years), who failed to achieve remission despite >6 months
induction therapy, underwent transthoracic echocardiography
(TTE) and cardiac magnetic resonance (CMR).
Results Cardiac involvement was present in 9 (82%)
patients. Regional wall motion abnormalities were found
in two individuals, but none had left ventricular (LV)
ejection fraction <50%. Nine patients had late gadolinium
enhancement (LGE) lesions involving LV myocardium and
right ventricle free wall was involved in four patients. LGE
lesions were found in subepicardial, midwall and subendo-
cardial LV myocardial layers. CMR revealed myocarditis in
six patients. Patients with myocarditis had a higher
number of LV segments with LGE (5.2±3.4 vs 1.0±1.2,
p=0.03) and more frequent diastolic dysfunction by TTE
(5 vs 0, p=0.02) than those without. Pericardial effusion
was observed in five patients, while localized pericardial
thickening in six patients.
Conclusions In WG resistant to >6 months induction
therapy cardiac involvement is frequent and is characterized
by foci of LGE lesions and signs of myocardial inflamma-
tory process.
Keywords Wegener’s granulomatosis . Cardiac magnetic
resonance . Echocardiography .Myocarditis . Remission
Introduction
Wegener’s granulomatosis (WG) is characterized by sys-
temic necrotizing vascultis and granuloma formation which
most often affects the respiratory tract and kidneys [1]. WG
is associated with a cytoplasmic pattern of antineutrophil
cytoplasmic antibodies (cANCA), with specificity against
proteinase-3. Although clinically evident cardiac manifes-
tations are rare, heart involvement is not uncommon and
varies substantially depending on disease activity and
diagnostic modality [1, 2]. A wide spectrum of cardiac
abnormalities including pericarditis, valvular lesions, coro-
nary arteritis, myocarditis and cardiac rhythm disorders
were described [3]. Cardiac involvement evaluated by
imaging has only been described in a few studies and most
cardiac abnormalities have been described in case reports
[2, 4, 5]. Recently, cardiac magnetic resonance (CMR) has
emerged as a novel technique providing comprehensive,
accurate assessment of myocardial function and structure
including detection of myocardial inflammation in patients
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suspected of acute and chronic myocarditis [6–8]. To date,
CMR evaluation of cardiac involvement in WG has been
limited to a single study and several case reports [9–11].
Cyclophosphamide and corticosteroids, which are pre-
dominately used for remission induction in life or organ
threatening WG, lead to clinical remission in the majority
of patients after 6 months of therapy [12]. Subsequent
treatment in patients who fail to achieve remission is poorly
defined and is based predominately on disease activity
assessment. In those patients no data exists regarding
cardiac involvement including signs of myocarditis. There-
fore the purpose of the present study was to evaluate
cardiac involvement by CMR in patients with WG who
failed to achieve remission despite >6 months induction
therapy for life or organ threatening disease (Fig. 1).
Methods
Study population The study group consists of eleven WG
patients who failed to achieve remission (defined as the
absence of signs of new or worse disease activity, with
persistent disease activity for ≤1 item according to
Birmingham Vasculitis Activity Score for WG [BVAS/
WG] score) within 6 months despite chemotherapeutic
treatment for life or vital organ threatening disease [13, 14].
The patients were retrospectively recruited in 2009/2010.
All patients fulfilled American College of Rheumatology
classification criteria and Chapel Hill Consensus Confer-
ence definition for WG [15, 16]. Exclusion criteria
included: a) limited WG or b) contraindication to CMR
including MR-incompatible implants or electronic devices,
renal insufficiency (creatinine clearance <60 ml/kg/min),
inability to perform breath hold and claustrophobia. Disease
activity was assessed using BVAS/WG score [13]. Organ
damage was measured using Vasculitis Damage Index
(VDI), and disease extent was assessed by Disease Extent
Index (DEI) [17, 18]. Sex- and age-matched healthy
individuals without known inflammatory and cardiovascu-
lar diseases served as controls to compare findings of CMR.
This study was approved by institutional ethics committee
and complied with 1975 Declaration of Helsinki. Informed
consent was obtained from each patient.
Combination of cyclophosphamide and glucocorticoids
was used for remission induction. Cyclophosphamide was
given intravenously at 15 mg/kg body weight (max 1.2 g)
Fig. 1 Late gadolinium enhancement (LGE) image (a) in four-
chamber apical view as well as TSE T2-weighted (b), pre- (c) and
post-contrast TSE T1-weighted images (d) in short axis view in
58-years old male with Wegener’s granulomatosis. LGE image shows
subendocardial fibrosis in left and right ventricle (arrows) (a). Mid
segments demonstrate increased T2 signal intensity (arrows) on TSE
T2-weighted image (b) suggesting myocardial edema and early
gadolinium enhancement (arrows) on post-contrast TSE T1-weighted
image (d) reflecting increased myocardial hyperemia/capillary leak.
Cardiac magnetic resonance revealed preserved global left ventricular
systolic function (EF=56%) with regional wall motion abnormalities
(akinesis of the apex, hypokinesis of apical anterior, lateral, septal and
mid anteroseptal segments)
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every 4 weeks for 6 months [19]. Concomitant glucocor-
ticoid therapy was initiated with intravenous methylopred-
nisolone (500–1000 mg) for 3 consecutive days, followed
by daily prednisone at 1 mg/kg body weight, which was
subsequently tapered with the goal to reach 10 mg/day
[19]. As patients failed to achieve remission at 6 months,
therapy was individualized and adapted to the disease
extent and activity. This therapy included combination of
low-dose glucocorticoids and either cyclophosphamide
(up to 1.5 mg/kg/day), azathioprine (up to 2 mg/kg body
weight) or methothrexate (up to 20–25 mg/kg body
weight/week) with the goal to use the lowest effective
dose and replace cyclophosphamide with azathioprine or
methothrexate, if possible [12, 19]. Rituximab was not
considered into drug regimen. All patients received
prophylaxis against pneumocystis infection and osteopo-
rosis [19].
Cardiac magnetic resonance: imaging protocol
Breath-hold, ECG gated CMR was performed at 1.5 T
(Magnetom Sonata Maestro Class, Siemens, Erlangen,
Germany) equipped with cardiac phased array coil. Cine
and morphologic imaging was performed in left ventricular
(LV) two-chamber, four-chamber and long-axis apical as
well as in short-axis view encompassing the entire LV. Cine
imaging was obtained using balanced steady-state free
precession gradient echo technique (slice thickness 8 mm,
no gap, matrix 256×192, in-plane resolution 1.3×1.3 mm,
TR/TE 39/1.1 ms, flip angle 59°). Morphologic images
were acquired with body coil using TSE T2-weighted
imaging (slice thickness 8 mm, no gap, matrix 256×154,
in-plane resolution 1.7×1.3 mm, TR depending upon RR
interval, TE 78 ms), and TSE T1-weighted imaging (slice
thickness 8 mm, no gap, TR depending upon RR interval,
TE 6,9 ms, flip angle 180°). TSE T1-weighted imaging was
performed before and early after intravenous infusion of
0.1 mmol/kg body weight gadobutrol (Gadovist, Bayer
Schering Pharma, Berlin, Germany). Following contrast
medium injection (10 min), late gadolinium-enhanced
(LGE) imaging was performed using T1-weighted
segmented inversion-recovery pulse sequence (slice thickness
8 mm, no gap, matrix 256×192, in-plane resolution 1.3×
1.3 mm, TR/TE 650/4.9 ms, flip angle 30°, TI set to null
normal myocardium).
Transthoracic echocardiography
Transthoracic echocardiography (TTE) was performed with
Vivid 7 ultrasound systems (GE Vingmed Ultrasound A/S,
Horten, Norway). Analysis was performed off-line by an
independent, experienced echocardiographer blinded to clinical
and CMR data. Left ventricular (LV) ejection fraction (EF),
end-diastolic volume (EDV) and end-systolic volume (ESV)
were calculated. LV diastolic dysfunction was evaluated in
accordance to guidelines published by the American Society of
Echocardiography [20].
Cardiac magnetic resonance: image analysis
TSE T1-weighted before and after contrast medium, TSE
T2-weighted, cine and LGE images were assessed off-line
using dedicated software (MASS Medis, Leiden, the
Nedtherlands) by two independent observers, blinded to
clinical and echocardiographic data. Discrepancies in
qualitative assessment were resolved by consensus. A
seventeen segment LV model was used for analysis.
Cine images LV short-axis as well as two-chamber, four-
chamber and long-axis apical views were used for
segmental wall motion analysis. Segmental myocardial
contractile function was scored as: 1-normal, 2-hypokinetic,
3-akinetic, 4-dyskinetic and expressed as wall motion score
index (WMSI). Endocardial and epicardial borders were
outlined on short axis images to calculate EDV, ESV,
myocardial mass and ejection fraction (EF). EDV, ESV and
myocardial mass were indexed to body surface area.
TSE T1- and T2-weighted images By quantitative analysis
mean T2 and T1 signal intensity (SI) (pre- and post-
contrast) were measured in a) individual LV segments, b)
entire LV myocardium at mid LV level in short axis view
and c) skeletal muscle (erector spinae or lattisimus dorsi)
in the same slice. T2 myocardial SI was related to
skeletal muscle SI and T2-SI ratio was calculated..
Myocardial early gadolinium enhancement (EGE) ratio
was calculated as myocardial to skeletal muscle enhance-
ment ratio. Global (i.e. determined in entire LV myocar-
dium) T2-SI ratio ≥2.0 and global EGE ratio ≥4 were
considered abnormal indicating myocardial edema and
myocardial hyperaemia/hyperpermeability of capillaries,
respectively [21]. By analogy, T2-SI ratio ≥2.0 and EGE
ratio ≥4 were considered abnormal for individual LV
segments.
LGE images LGE images were assessed qualitatively for
the presence and location of hyperintense lesions in
contrast to hypointense viable myocardium. The number
of affected segments was calculated and right ventricular
(RV) involvement was determined. LGE lesions in LV
myocardium were defined as transmural, subendocardial
(adjacent to endocardium), midwall and subepicardial
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(adjacent to epicardium). Based on visual assessment of
distribution LGE lesions were classified as non-ischaemic
or ischaemic [21].
Myocardial inflammation According to Lake Louise Criteria
CMR was considered to indicate myocardial inflammation,
when ≥2 of following criteria were present: a) global T2-SI
ratio ≥2.0, b) global EGE ratio ≥4 and c) ≥1 focal non-
ischaemic LGE lesion [21].
Statistical analysis Categorical data are presented as numbers
or percentages, while continuous data as mean ± standard
deviation or median with interquartile range, where
appropriate. The normal distribution was verified using
Shapiro-Wilk test. Categorical variables were compared
by Fisher’s exact test, while continuous variables by
unpaired student t-test or Wilcoxon rank-sum test. Pearson
product-moment correlation was performed to assess
relationship between the extent of LV damage and
parameters reflecting WG activity. Statistical analyses
were performed using SPSS software (version 12.0, SPSS
Inc., Chicago, IL, USA). Differences were considered
statistically significant at p<0.05.
Results
Baseline characteristics Eleven WG patients (eight males,
three females, mean age 47±13 years) underwent TTE and
CMR successfully. Clinical characteristics including indi-
vidual organ involvement are presented in Tables 1 and 2.
cANCA with anti-proteinase-3 specificity were found in all
patients. Two patients had symptomatic heart failure
(NYHA II and NYHA III), and one had typical stable
angina (CCS III). All of them underwent coronary
angiography which revealed no significant coronary artery
stenoses. One patient had a history of prior myocardial
infarction. No coronary artery revascularization was per-
formed. At enrollment no patient showed AV-block on ECG
although one demonstrated transient AV-block (grade III)
during disease exacerbation.
CMR and TTE CMR characteristics are summarized in
Table 3. No WG patient had global LV or RV systolic
dysfunction, defined as LVEF <50% and RVEF <40%,
respectively. Both patients with heart failure symptoms
demonstrated segmental LV wall motion abnormalities
(apical hypokinesis [WMSI=1.06] in one patient and
akinesis of the apex with hypokinesis of the apical anterior,
lateral and septal as well as mid anteroseptal segments
[WMSI=1.35]) in another). According to Lake Louise
Criteria CMR demonstrated myocardial inflammation in six
WG patients. Pericardial effusion was found in five patients
and localized pericardial thickening in six patients. The
latter finding tended to be more frequent in those with than
without CMR signs of myocarditis (5 vs 1; p=0.08).
Comparing patients with and without CMR signs of
myocarditis, the former had more frequent diastolic
dysfunction detected by TTE (5 vs 0, p=0.02) and a higher
index of LV mass (72.6±9.4 vs 57.8±7.7, p=0.02). No
differences in the prevalence of hypertension (3 vs 3, p=
1.0) or diabetes mellitus (1 vs 1, p=1.0) was observed
between both groups. All individuals with LV diastolic
dysfunction demonstrated an impaired relaxation pattern
and none demonstrated a pseudonormal or restrictive
diastolic dysfunction pattern. Comparing patients with or
without CMR signs of myocarditis no differences in actual/
last flare DEI or BVAS/WG score were found and both
groups showed similar cumulative VDI score at enrollment.
LGE lesions were observed in LV or RV myocardium in
nine and four patients, respectively. Patients with CMR
signs of myocarditis had more LV segments with LGE than
those without myocarditis (5.2±3.4 vs 1.0±1.2, p=0.03).
LGE lesion were found in all LV myocardial fiber layers
(5 subendocardium, 5 midwall and 4 supepicardium) and
were transmural in two patients. Of 31 LV segments with
LGE lesions, 15 were localized in the inferior and posterior
walls and 13 were apical. No correlation was found
between the number of LV segments with LGE and
actual/last flare DEI, BVAS/WG score, serum C-reactive
protein, cANCA or cumulative VDI score (r<0.4, p=NS for
all correlations). TTE demonstrated thickened mitral valve
leaflets in six and thickened aortic valve leaflets in three
patients. No patient demonstrated moderate or severe
valvular regurgitation or stenosis.
Discussion
This is the first comprehensive evaluation of heart
involvement in patients with life or organ threatening WG
who were resistant to induction therapy. The heart was
frequently involved and the majority of WG patients
demonstrated LGE lesions distributed in all myocardial
layers. Moreover, many patients showed signs of myocar-
dial inflammation, which was associated with diastolic
dysfunction.
Although clinical cardiac involvement is not common in
WG, there is growing evidence of subclinical heart
involvement during the course of this disease [2–5]. Previous
studies showed the wide spectrum and varied prevalence of
cardiac abnormalities in WG, which has been linked to the
disease activity [3]. We found that heart involvement is very
frequent in WG patients who despite >6 months induction
therapy failed to achieve remission. In the majority of
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patients cardiac involvement was subclinical and only two
patients manifested cardiac symptoms (heart failure) at
enrollment. The most frequent abnormality observed in the
present study was LGE lesions in both RV and LV
myocardium. LGE lesions were previously described in case
reports of WG and similar to the present study, they were
distributed in all myocardial layers (subendocardial, midwall,
subepicardial) [9–11]. Interestingly, many of them were
localized in apical and posteroinferior LV wall segments
and a similar distribution of myocarditis was reported at
autopsy in a patient with rapidly progressive, fatal WG [22].
However, other distributions of myocardial involvement
were also described [9–11]. In contrast to the present study,
Mavrogeni et al. [4], who performed CMR in eleven WG
patients, did not observe LGE myocardial lesions. This
apparent discrepancy may have several explanations. First,
WG patients described by Mavrogeni et al. [4] had less
active disease. As such, they may have not developed
necrotic/fibrotic myocardial lesions or such lesions may have
resolved during the course of well controlled disease. Indeed,
regression of LGE lesions were reported by Mahrhold et al.
[23] following viral myocarditis. Second, patients enrolled
by Mavrogeni et al. [4] had no history or evidence of cardiac
disease (versus four such patients in the current series).
Third, the high threshold for signal intensity to delineate
LGE lesions used by Mavrogeni et al. [4] may have reduced
the ability to detect such lesions. Prior studies which
evaluated non-ischemic myocardial damage used lower
thresholds for LGE detection. [23, 24] In the current study,
LGE lesions were more frequent in patients with CMR signs
of myocardial inflammation. Nevertheless, these lesions
were frequently located in LV myocardial segments without
CMR signs of myocardial oedema or hyperaemia/hyper-
permeability of capillaries suggesting rather healed than
necrotic lesions. In the majority of patients LGE lesions were
not associated with regional wall motion abnormalities. In
this regard, Mahrhold et al. [25] demonstrated that non-
transmural or transmural of low volume LGE lesions
following myocardial infarction rarely cause contractile
abnormalities.
The assessment of WG disease activity is crucial to
guide treatment and assess prognosis. Our study is the
Table 2 Patient characteristics
Parameters CMR evidence of myocarditis All patients (n=11)
Yes (n=6)/no (n=5)
Female/Male 1/5/2/3 3/8
Age [years] 51.3±12.3 / 43.8±16.4 46.7±13.2
Time: diagnosis to CMR[months] 55.5±34.8 / 66.0±63.3 60.3±47.3
Time: last flare to CMR [months] 18.7±10.0 / 18.4±14.8 18.5±11.7
Time: end of induction therapy to CMR [months] 12.7±10.0 / 12.4±14.8 12.6±11.7
Last flare
DEI 9.0±1.1 / 8.0±3.1 8.6±2.2
BVAS/WG score 12.5±3.4 / 12.5±4.0 12.5±3.5
cANCA titre 80(80–80) / 80(40–400) 80(50–260)
CRP [mg/l] 71±62 / 74±56 72±57
Creatinine clearance [ml/min] 97±49 / 87±40 93±43
Enrolment
DEI 6.0±1.8 / 5.2±2.2 5.6±1.9
BVAS/WG score 4.2±1.5 / 4.6±1.7 4.4±1.5
Cumulative VDI score 7.8±0.8 / 7.2±2.6 7.5±1.8
cANCA titre 30 (20–40) / 20 (10–70) 20 (12.5–40)
CRP [mg/l] 6.9±6.6 / 7.4±7.4 7.1±6.6
Creatinine clearance [ml/min] 90±48 / 105±34 97±41
Exertional dyspnea 1/1 2
NYHA class I/II/III/IV 0/1/0/0 / 0/0/1/0 0/1/1/0
Angina pectoris 0/1 1
CCS class 1/2/3/4 0/0/0/0 / 0/0/1/0 0/0/1/0
No statistical differences between patients with and without CMR signs of myocarditis were found
CMR cardiac magnetic resonance, BVAS/WG Birmingham Vasculitis Activity Score for Wegener’s granulomatosis, CCS Canadian Cardiovascular
Society classification system for angina pectoris, cANCA cytoplasmic pattern of antineutrophil cytoplasmic antibodies, CRP C-reacitive protein,
DEI Disease Extent Index, NYHA New York Heart Association classification system for heart failure, VDI Vasculitis Damage Index
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first to demonstrate that CMR signs of myocarditis are
frequent in patients with WG who fail to achieve
remission despite >6 months induction therapy. If
compared to our study, prior reports suggested lower
prevalence of myocarditis in WG [26]. The high
prevalence of myocardial inflammation may reflect
increased disease activity and/or high disease affinity for
heart in those who are resistant to induction therapy. This
may be clinically pertinent since heart involvement is
recognized as a factor predicting relapse [27]. The signs
suggestive of myocarditis were accompanied by higher
prevalence of LGE lesions and localized pericardial
thickening indicating more severe and extensive inflam-
matory process. Clinical and prognostic implications of
CMR findings in WG are unknown and their responsive-
ness to immunosuppressive therapy remains to be deter-
mined. Interestingly, Caudron J et al. [10] previously
demonstrated regression of CMR detected myopericarditis
after 3 months treatment with corticosteroids and cyclo-
phosphamide. Similarly, regression of CMR-diagnosed
myocarditis following rituximab therapy, which was
administered when conventional regimens failed to control
disease, were described [9]. In the present study, the
majority of patients with CMR evidence of active
myocarditis demonstrated diastolic dysfunction on TTE,
which may reflect increased LV wall stiffness. Patients
with CMR signs of myocarditis had a larger LV mass
index which could be partially explained by the presence
of myocardial edema although hypertrophy secondary to
hypertension cannot be excluded. As diastolic dysfunction
was present in the majority of patients with active
myocarditis, TTE may serve as a screening tool before
CMR is performed.
Study limitations First, the number of enrolled patients is
low and the results should be confirmed in larger patient
cohort. Second, due to contraindication to CMR we
excluded patients with low creatinine clearance so the
results may not apply to the larger population of WG
patients. Third, CMR criteria recommended to identity
myocardial inflammation are based on studies over sus-
pected acute or chronic viral myocarditis, and were not
validated when inflammation is caused by autoimmune
process. Finally, endomyocardial biopsy was not performed
to confirm the presence of myocarditis. It is known,
however, that endomyocardial biopsy has a poor diagnostic
accuracy due to patchy myocardial involvement in WG
[22].
Conclusions
Cardiac involvement is frequent in patients with life or
organ threatening WG who fail to achieve remission
despite >6 months induction therapy. Most patients
demonstrate LGE lesions, which may reflect both
necrotic and fibrotic lesions. Moreover, heart disease is
Table 3 CMR findings
CMR Parameters CMR evidence of myocarditis in WG WG patients (n=11)/Matched
controls (n=11)Yes (n=6)/no (n=5)
LVEF [%] 65.0±5.5 / 62.8±5.6 64.0±5.4 / 61.4±3.2
LVEDV index [ml/m2] 72.0±19.5 / 67.8±15.4 70.1±17.0 / 72.6±12.8
LVMass index [g/m2] 72.6±9.4 / 57.8±7.7 65.9±11.3 / 58.1±9.0
RVEF [%] 59.7±6.1 / 50.6±10.6 55.6±9.3 / 52.7±6.6
RVEDV index [ml/m2] 70.9±13.8 / 71.8±23.0 71.3±17.5 / 73.2±9.1
RVMass index [g/m2] 17.5±3.6 / 14.9±4.3 16.7±2.7 / 16.3±3.9
Myocardial SI-T2 ratio at mid LV level 1.8±0.5 / 1.3±0.1 1.5±0.5 / 0.7±0.4****
Myocardial EGE ratio at mid LV level 4.1±0.5 / 2.3±0.5** 3.3±1.0 / 2.3±0.9***
Pericardial effusion 3/2 5/0***
Localized pericardial thickening 5/1 6/0***
LVLGE: present 6/3 9/0****
LVLGE: segment number 5.2±3.4 / 1.0±1.2* 3.3±3.3 / 0.0±0.0****
RVLGE: present 3/1 4/0
RVLGE: segment number 1.0±1.3 / 0.4±0.9 0.7±1.1 / 0.0±0.0***
*p<0.05, **p<0.001 for patients with versus without CMR signs of myocarditis
***p<0.05, ****p<0.001 for WG patients versus controls
CMR cardiac magnetic resonance, EGE early gadolinium enhancement, EF ejection fraction, EDV end-diastolic volume, LGE late gadolinium
enhancement, LV left ventricular, RV right ventricular, WG Wegener’s granulomatosis
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frequently characterized by myocardial inflammatory
process. As myocardial inflammation was frequently
associated with diastolic dysfunction on TTE, this
modality may serve as a screening tool for myocarditis
in WG. The present study suggests that CMR appears to
be the most sensitive non-invasive diagnostic technique
to assess heart involvement in WG.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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